Serum Digoxin Levels Related to Plasma Propafenone Levels During Concomitant Treatment

Publisher Website
Google Scholar
Abstract
Nine patients with supraventricular rhythm disorders were treated during 5‐day periods with different oral doses (300, 450, 600, and 900 mg daily) of propafenone concomitantly to long‐term digoxin treatment. A poor correlation (r = .398; P <.05) was obtained when the difference between the mean digoxin serum level (calculated with the Cmin data determined each of the 5 days) observed during a given propafenone dose and the mean digoxin serum level observed before propafenone treatment, was correlated with the dose of propafenone; but an evident correlation (r = .778; P <.01) was found when the difference in digoxin level was correlated with the plasma propafenone concentration. The propafenone effect of increasing digoxin blood levels was thus concluded to be poorly dose dependent but strongly concentration dependent. The association of propafenone to a long‐term digoxin treatment can be considered with a low risk of toxicity when plasma propafenone concentration does not exceed about 1000 ng/mL. Propafenone plasma levels are unpredictable in view of their wide interindividual variation for a given dose, so their measurement is advised to detect high levels and consequently to prevent a rise in digoxin serum concentrations with the possibility of toxicity. In clinical practice, when propafenone concentration determinations are not readily available, digoxin serum levels at least have to be carefully monitored.

This publication has 11 references indexed in Scilit: